CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today reported first quarter 2021 financial results and provided a business update.

Click to view original post